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Introduction 
Venous malformations are composed of thin-walled channels, deficient in 
smooth muscle, that are lined by quiescent endothelium.  They usually occur in a 
pure form; however, they can be combined, such as capillary-venous 
malformation or lymphatic-venous malformation. These malformations are usually 
congenital (i.e., obvious at birth), but they also often appear in childhood or 
adulthood. They grow proportionately with the patient and do not regress.9  
Symptoms are related to size and location. Many venous malformations 
are superficial cutaneous blemishes. Deep cutaneous or intramuscular lesions 
usually cause discomfort, often in the early morning on awakening or with 
exertion. Intraoral venous malformations can bleed, distort dentition, cause 
speech problems, or obstruct the upper airway and pharynx. Thrombosis, 
swelling, and pain are common in all venous malformations. The most accurate 
radiologic techniques for delineating venous malformations are magnetic 
resonance imaging (MRI) and direct injection venography. These anomalies 
exhibit high signal intensity on spin-echo T2-weighted MRI sequences. They 
opacify poorly or not at all by arteriography.19 
The various modalities of treatment are either surgical or non surgical. 
Complete excision seldom achieved because of the complicated facial anatomy 
and usually may lead to nerve damage, massive bleeding and cosmetic 
deformity. Among the non surgical ones sclerotherapy is the most preferred. It 
acts by obliteration of the channel lumens by damaging endothelium with 
subsequent inflammation & fibrosis. Thus, it has advantages of few complications 
and no external scarring  
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The two most common agents used are Ethanol and Sodium tetradecyl 
sulphate. Sodium tetradecyl sulphate has drawback that a limited dose can be 
given in one sitting thus requiring multiple sessions. It is also less potent as 
compared to ethanol with greater tendency for recanalization. 
Ethanol on the other hand can be given upto 1ml/kg body weight .It is the 
most reliable sclerotherapeutic substance with lowest rate of malformation 
recurrence.Thus, keeping in view above facts we planned to evaluate the role of 
direct percutaneous ethanol instillation in venous malformations of the face and 
neck. 
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Aims and Objectives 
1. To evaluate the efficacy of Direct Percutaneous Ethanol Instillation in Venous 
Malformation of the Face and Neck. 
2. To study the side effects of ethanol sclerotherapy in venous 
malformations of face and neck. 
3. To study factors that might predict the result of sclerotherapy. 
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Materials & Methods 
This is a one and half years prospective study from July 20, 2008 to 
December 31, 2009 of fifteen patients with the diagnosis of venous malformation in 
the face and neck treated with direct percutaneous ethanol instillation in the 
Department of Plastic Surgery, Christian Medical College & Hospital, Vellore. 
Informed consent was obtained from all the patients. This study was approved by 
the Institutional Review Board of the Christian Medical College & Hospital, Vellore. 
Procedure 
The diagnosis was confirmed by a combination of history, physical findings 
and Magnetic Resonance Imaging. Percutaneous Ethanol (99.5% ethyl alcohol) 
Sclerotherapy was given in the DSA Room under all aseptic precautions by 
experienced Radiologists. After the induction of general anesthesia, intravenous 
fluid was administered, a urinary catheter was placed, and the facial site 
prepared and draped in a sterile manner. Rubber Bands were used to compress 
the patient’s forehead and chin to occlude the facial venous return. Under 
ultrasound guidance, venous spaces were cannulated using one or more no. 23G 
scalp vein needles, Blank Road Map was taken and contrast Medium was under 
DSA (Siemens Multistar) till the deep vein opacification was seen. The volume of 
contrast injected by syringe was used to determine the volume of venous 
cavities. Any contrast injection draining immediately to deep vein was avoided for 
sclerotherapy. The course of the deep veins also evaluated, especially to exclude 
any intracranial course of the deep veins.  
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Fig (1) Rubber bands to occlude the facial venous return 
 
Fig (2) DSA showing contrast in the background of Blank Road Map 
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Fig (3) Contrast being injected 
 
Fig (4) Ethanol injection being administered in the cavity. 
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After assessing the volume of cavity; injection of 99.5% ethanol one third the cavity 
volume (not exceeding the maximum recommended dose of 1ml/kg body weight) was 
injected into the tumor cavities under DSA and catheter was withdrawn. Manual 
compression was maintained for 5 minutes to fix the solution in the clot and the vein walls. 
All patients received intravenous hydration for 4 to 24 hours after sclerotherapy, generally 
at twice the maintenance rates. Urinary output was monitored for volume and color. All the 
patients were observed overnight in the hospital. All the patients were given a 
corticosteroid, 0.1 mg/kg dexamethasone, immediately before the procedure and every 8 
hours while in the hospital. After discharge from the hospital, prednisolone was given at 2 
mg/kg/day in three divided doses, which was tapered over 5 days. Repeat course of 
injection 99.5% ethanol was administered after an interval of 12 weeks from the 
previous injection if abnormal venous channels persisted. Treatment success was 
determined by reduction in lesion size on MRI. All the patients were followed up for 
a minimum of 3 months after the last session of sclerotherapy and were graded by 
the following grading criteria: 
Grading 
Good      Complete Disappearance of symptoms  
including clinical obliteration 
Fair  Decrease in size and symptoms 
Poor   Little or no improvement 
Inclusion Criteria: All patients between 2 years and 65 years of age  
Exclusion Criteria: All patients below 2 years and above 65 years of age. 
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Statistical Analysis 
The following statistical method has been applied: 
1. Paired t test 
2. Spearman’s rank correlation coefficient 
3. Scatter plot 
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Review of Literature 
Venous malformations (VMs) are a commonly encountered entity in 
clinical practice, with an estimated incidence of 1 to 2 in 10,0001births and a 
prevalence of 1%[2] and [3]. 
For several centuries, a myriad of cutaneous or visceral masses, 
pigmentations, or spaces that resulted in a predominantly disturbed vascular 
morphologic pattern were named and categorized according to appearance, 
location, fluid content, and often inconsistent or unpredictable clinical behaviour.4 
Until only recently, this purely descriptive nomenclature resulted in a 
severely bloated lexicon that was redundant, difficult to understand or 
conceptualize, and predisposed to frequent misdiagnosis and incorrect 
management.5 Further understanding of etiology, disease process relationships, 
and the development and testing of novel therapies was also impeded because 
these earlier categorization schemes were not founded on the currently accepted 
belief that a much smaller group of vascular defects or entities are responsible for 
the protean clinical appearances and manifestations of most vascular anomalies. 
Over time, experienced multidisciplinary vascular anomaly teams have 
evolved that allow the establishment of clear lines of communication and the use 
of the most current clinical, pathologic, and image-based standards available.6-8 
Historical Background 
Because most vascular anomalies involve the skin to variable degree they 
tend to be visible and have consequently received colorful appellations since 
ancient times. As recently as the nineteenth century, causative factors implicating 
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the mother resulted in names such as naevus maternus or “mother's mark.”9 
Other systems used food descriptors, such as strawberry, port-wine, or cherry, 
terms that unfortunately still persist in common medical parlance today.[5]and[10] 
Virchow and Wegner developed histologic-based classification schemes for 
vascular anomalies in the later nineteenth century. Vascular lesions were 
considered to be vascular tumors and were further subdivided into angioma 
simplex (later known as the “capillary” or “strawberry” hemangioma); angioma 
cavernosum (later used to describe both the infantile hemangioma or the VM); 
and the angioma racemosum (used to describe a cirsoid aneurysm or 
arteriovenous hemangioma).[5],[9],[10], [11]and[12] This classification hypothesized an 
underlying cause of abnormal vascular cellular proliferation or dilatation at work, 
but did little to address the biologic behavior of these lesions.10 As early as 1932, 
De Takats13 proposed that these angiomas represented persistent rests of 
embryonic angioblastic tissue that failed to resorb fully or differentiate because of 
aberrations in vasculogenesis occurring in specific stages of embryonic 
development. The concept of these lesions being tumors persisted in the 
literature, 14 however, fostering the ubiquitous use of the term “hemangioma” that 
was often accompanied by host of prefixes. This practice continued throughout 
the remainder of the twentieth century, perpetuating the disconnect between 
misleading nomenclature and the true biologic nature of the lesion its name was 
meant to describe. 
By 1971, there was general agreement by attendees of the International 
Symposia on Angiological Nosology in Florence that a new vascular anomaly 
classification scheme “was absolutely necessary for didactic and practical 
purposes” that was to be “in so far as possible, schematic and simplified.”15 As a 
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result, based on the concepts proposed by Malan16 and described by Degni and 
coworkers,[17]and[18] congenital vascular defects were simply categorized as 
predominantly arterial, venous, arteriovenous, lymphatic, or mixed. 
In 1982, in a landmark publication, Mulliken and Glowacki9 proposed what 
would become the foundation of modern vascular anomaly classification. Based 
on the lesion's biologic and pathologic differences, all vascular anomalies were 
assigned to one of two broad categories: hemangiomas and vascular 
malformations (Table 1).       
Hemangiomas were described as those exhibiting rapid neonatal growth 
and hypercellularity during a proliferating phase, followed by an involutive phase 
characterized by diminished cellularity and fibrosis. This former category was 
later expanded to include vascular tumors. The suffix “-oma” was only to be 
reserved for those lesions exhibiting increased cellular turnover, the classic 
example within this category being the infantile hemangioma.  
The term “vascular malformation” was applied to those lesions present at 
birth growing commensurately or pari passu with the child. The vascular 
malformations were composed of normal “mature” flat endothelial-lined vascular 
spaces with normal rates of cell turnover and were further subdivided into 
capillary malformation; VM; arterial (arteriovenous malformation [AVM]); 
lymphatic malformation (LM); and fistulae initially. In 1983, Burrows and 
coworker13 incorporated angiographic differentiation and flow characteristics into 
the classification. 
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Table -1 
Classification of vascular lesions in infants and children 
 
 
         In 1988, at the 7th Meeting of the ISSVA in Hamburg, the work of Malan, 
Degni, and Belov formed the “Hamburg Classification” of vascular defects (Table 
2). 
In 1993, Jackson and coworkers20 later identified the need for further 
augmentation of Mulliken's classification to “answer the (therapeutic) questions of 
‘what to do’ and ‘when to do it’.” He elegantly simplified flow patterns within 
vascular malformations as either low flow (VMs) or high flow (AVMs), keeping 
separate categories for LMs and hemangiomas, with the purpose of creating a 
“system directly related to investigation and treatment” (Box 1). LMs have since 
been subdivided into macrocystic, microcystic, and mixed varieties based on 
lesion cavity size. For simplicity, many now consider LMs to reside in Jackson's 
low-flow category 
 
Hemangiomas Malformations 
Proliferating phase Capillary 
Involuting phase 
Venous 
Arterial 
Lymphatic 
Fistulae 
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Table - 2 
Anatomopathologic classification of vascular defects (Hamburg 
classification) 
Type 
Forms 
Truncular Extratruncular 
Predominantly arterial defects 
Aplasia or obstructive Infiltrating 
Dilatation Limited 
Predominantly venous defects 
Aplasia or obstructive Infiltrating 
Dilatation Limited 
Predominantly lymphatic defects 
Aplasia or obstructive Infiltrating 
Dilatation Limited 
Predominantly AV shunting 
defects 
Deep Infiltrating 
Superficial Limited 
Combined/mixed vascular defects 
Arterial and venous Infiltrating hemolymphatic 
Hemolymphatic Limited hemolymphatic 
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                         Box- 1 
Classification of vascular anomalies by vascular dynamics 
I. Hemangioma  
II. Vascular malformations  
a. Low-flow (VM)  
b. High-flow (AVM) 
III. LM 
 
In 1992 at the ISSVA meeting in Colorado, a final nosologic consensus 
clarified the umbrella term of “vascular anomaly” to describe all vascular tumors 
and malformations and the use of the suffix “-oma” to refer only to lesions 
demonstrating cellular hyperplasia.21 The final modern classification of vascular 
anomalies after Mulliken based on histology, clinical behavior, and flow 
characteristics was adopted at the ISSVA in Rome 1996,21 with the most recent 
and complete version appearing in 2007 (Table 3).22 
 15
Table - 3  
International society for the study of vascular anomalies classification of vascular 
anomalies 
Tumors 
Vascular Malformations 
Simple Combined 
Infantile hemangioma Capillary (C) Arteriovenous fistula 
Congenital hemangioma Lymphatic (L) 
Arteriovenous malformation 
(AVM) 
Tufted angioma Venous (V) CVM 
Kaposiform 
hemangioendothelioma  CLVM 
Hemangiopericytoma  LVM 
Pyogenic granuloma  CAVM 
Spindle-cell 
hemangioendothelioma  CLAVM 
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Gross Inspection 
VMs are composed of abnormal collections of veins that have a variable 
luminal size and wall thickness and geographically can appear superficial, deep, 
diffuse, localized, and not uncommonly multiple.23 The lesions are often less well 
circumscribed than vascular tumors, such as infantile hemangiomas23, and can 
be interspersed with adipose tissue or within variably atrophic or degenerative 
muscle.[8] and [24] 
Conventional Microscopy 
As with all vascular malformations, conventional hematoxylin-eosin 
staining techniques for VMs reveal irregular variably dilated or thickened 
dysplastic-appearing vascular channels lined with flat mature endothelial cells in 
contrast to hypercellularity seen in vascular tumors.[9],[10],[23]and[24] These vascular 
spaces are usually filled with an abundance of erythrocytes. Capillaries and 
venules may reside within the VM substance. In addition to the absence of 
internal elastic lamina, there is a relative paucity or intermittent absence of 
smooth muscle within the VM channel wall[8]and[23] with occasional locules of 
disorganized smooth muscle identified emanating from the vascular wall into the 
surrounding stroma23 Localized intravascular coagulopathy is frequently present 
within VMs25 and as a result, luminal thrombi can develop and become calcified 
and form phleboliths.  
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Immunohistochemical Staining 
Although the vascular channels in VMs are surrounded by a normal 
reticulin network,9 anti-smooth muscle α-actin stains reveal an absent or patchy 
mural smooth muscle distribution in clumps, which is thought to be the major 
causative factor in the histologically observed vascular ectasia that results in the 
mass-like appearance of VMs.[26], [27], [28] and 29] 
     In cases of mixed or ambiguous histology, the addition of 
immunohistochemical staining to a detailed clinical and imaging work-up may be 
required to arrive at the correct diagnosis. All vascular malformations are 
negative for glucose transporter-1 that is expressed exclusively by infantile 
hemangiomas.30 D2-40, a monoclonal antibody to oncofetal antigen M2A, is 
highly avid for normal lymphatic endothelium and interestingly also within 
kaposiform hemangioendotheliomas.[31],[32],[33]and[34] This allows discrimination 
between VMs and frequently similar appearing LMs (particularly microcystic 
varieties) with the former staining negative for this antibody and the latter staining 
positive.33  
Developmental etiology of venous malformations 
Because many vascular malformations are not clinically obvious in early 
life, it is not generally appreciated that all vascular malformations are present at 
birth.23 For that reason, it has long been held that a localized defect or defects 
within vascular morphogenesis is responsible for all vascular malformations 
whether caused by hereditable or sporadic mutation, altered gene expression, or 
environmental factors. To comprehend the hypothesized mechanisms leading to 
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the development of a VM, one must first possess an understanding of normal 
vascular morphogenesis. 
Embryology: Vascular Morphogenesis 
The cardiovascular system is the first functional system to form in the 
embryo35 and begins development at approximately 13 to 15 days gestation with 
the urgent embryonic need for increased nourishment and oxygenation. Vascular 
morphogenesis is divided into two phases. The first phase, termed 
“vasculogenesis,” begins in the extraembryonic mesoderm of the yolk sac.36 
Mesodermal hemangioblasts congregate into clusters of blood islands that 
cavitate centrally. Outer layers differentiate into endothelial progenitors called 
angioblasts,37 whereas the inner layers form primitive plasma and blood cells.36 
These “shells” organize to form a lattice of short tubes or canaliculi that constitute 
the primary capillary plexus. The second phase, angiogenesis, occurs as a result 
of four distinct processes.[38],[39]and[40] Sprouting results in additional capillaries 
“budding” from existing capillaries. Nonsprouting occurs as a result of 
extracellular matrix transcapillary pillars or posts cleaving or fusing existing 
vessels. These first two processes occur simultaneously on the primary capillary 
plexus to create a juvenile vascular network. Further deletions are made in the 
juvenile network through the third process of pruning. The fourth and final 
process, termed “maturation,” occurs as a result of an interaction between the 
primitive endothelium and the surrounding mesenchyme to form fully 
differentiated smooth muscle cells and pericytes-adventitia surrounding mature 
endothelium. This gives rise to a fully differentiated multilayered vascular 
structure within a mature circulatory system. 
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Molecular Genetics: Endothelial-Pericyte Interactions 
Given the histologic abnormalities of the smooth muscle–pericyte 
component within vascular channel walls of VMs, it is not surprising that a 
hypothesized defect in this interaction has garnered a great deal of attention by 
molecular biologists as a potential cause of many VMs.38 In a recent study of 
1685 patients, 98.8% of VMs occurred sporadically in a noninherited fashion.41 
The few inherited varieties often appear as multifocal lesions clinically.[42],[38]and[43] 
Some entities are thought to be the result of mosaicism.44 The molecular biologic 
study of these inherited lesions allows a more complete understanding of the 
genes coding for endothelial cell–mesenchymal pericyte interaction and those 
genes and proteins that are responsible for the observed malformation 
phenotypes.[1], [42], [26], [30], [28], [35], [45], [46], [47] and [48] 
The study of a rare autosomal-dominant inherited condition named 
“familial cutaneomucosal VM,” characterized by the appearance of multiple 
cutaneous and mucosal VMs within two separate families, reveals a genetic 
linkage to a locus on the short arm of chromosome 9.[42]and[43] Identical R849W 
mutations occurred in the region coding for the tyrosine kinase or TIE-2 
receptor.[36]and[47] In addition to this location, later studies have found another 
Y897S mutation within the TIE-2 gene.48 Located on the surface of the 
endothelial cell, TIE-2 is critical to maintaining this multilayer vascular stability 
between endothelial cells and smooth antagonizes the Ang-1 signal on the TIE-2 
receptor, leading to loss of endothelial cell perivascular cell adherence 
(disassembly), which allows for more sprouting.[35],[49]and[51] In animal models of 
underexpression of Ang-1, overexpression of Ang-2, or absence of the TIE-2 
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receptor, vasculogenesis proceeds normally; however, disrupted angiogenesis 
results in disordered vascular assembly.[49],[50]and[51] 
During angiogenesis, freshly sprouted endothelial cells induce the 
surrounding mesenchyme to express platelet-derived growth factor receptor-β. 
The new endothelial cells secrete platelet and -derived growth factor B, which 
interacts with the mesenchymal receptor leading to smooth muscle proliferation 
and adherence.54 The interaction between pericyte muscle cells during 
angiogenesis through activation-inactivation by the angiopoietin (Ang) family of 
ligands.[44],[52],[49],[53]and[50] Late in angiogenesis (or in nonhypoxic states), Ang-1 
produced by the surrounding smooth muscle cell stimulates the TIE-2 receptor on 
the endothelial cell promoting smooth muscle cell–pericyte proliferation and 
adherence to the endothelial cells (assembly). Early in angiogenesis (or 
hypoxemic states) vascular endothelial growth factor leads to the endothelial cell 
production of Ang-2, which endothelium is also mediated by transforming growth 
factor-β1 signalling, which is critical for smooth muscle differentiation. 
Glomuvenous malformation is an autosomal-dominant inherited subtype of 
VM resulting in multiple raised purple subcutaneous nodular VMs surrounded by 
“glomus cells” within the extremities that are painful on palpation.[1],[26],[35]and[46] 
The entity accounts for 5.1% of all VMs and is inherited in 63.8% of cases.41 A 
mutation at chromosome 1p21-22 coding for previously unknown protein glomulin 
is thought to be responsible.55 Based on anti–smooth muscle α-actin staining and 
electron microscopy, glomus cells are thought to be deranged smooth muscle 
cells.[56],[57]and[58] Glomulin is normally thought to control differentiation of smooth 
muscle cells by competitively inhibiting inhibitors of the transforming growth 
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factor-β1 pathway.[46]and[58] In the mutated state, this effect is lost, leading to the 
glomuvenous malformation phenotype. 
Klippel-Trénaunay syndrome has recently revealed three chromosomal 
abnormalities resulting in “increased” angiogenesis.[61] and [60] Genetic analyses of 
many other VM-containing syndromes are ongoing. 
Clinical Presentation and Diagnosis 
The diagnosis of VM and differentiation from other malformations can 
usually be made purely by clinical history and physical examination. Although all 
VMs are present at birth,23 they may not be identified until later in childhood or 
young adulthood. Usually, the period of greatest enlargement of the lesion occurs 
from infancy to puberty.22 Occasionally, the VM may be of insufficient size during 
the childhood phase of pari passu or commensurate lesional growth and may 
escape detection. With the end of somatic growth in later adolescence, however, 
continued linear growth within the malformation often results in clinical 
manifestations later in life and is typically the case in deeper lesions.62 Adults 
presenting with the erroneous label of “acquired” VM on closer questioning often 
give a history of the formative lesion or related symptoms being present for years 
to decades earlier.9 Some have reported accelerated growth because of trauma, 
hemorrhage, partial resection, or the hormonal influences of pregnancy.[29] and [63] 
Those patients with visible VMs are, as expected, the most common 
referrals to vascular anomaly centers.8 These lesions are typically soft, 
compressible variably blue-tinged masses that can enlarge with dependant 
positioning and Valsalva.64 The blue tinge is considered pathognomonic and is 
caused by the known dilated venous channels within the dermis.22 The lesions 
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may also possess associated superficial ecchymoses, telangiectasias, or 
varicosities. Unlike AVMs, there is no hyperemia, increased temperature, 
pulsatility, or palpable local thrill. 
Forty percent of VMs occur in the head and neck region[29]and[63] and may involve 
mucosal surfaces of the tongue, palate and orbital, mandibular, or neck region. 
Mandibular lesions typically present as a painless slow-growing masses that 
infiltrate bony structures, dentition, and affect speech and lead to dysphagia. 
Local infiltration can cause orbital or ocular issues or airway obstruction.[22]and[65] 
Comparative Imaging Diagnosis of Venous Malformations 
Although the diagnosis of most cutaneously visible or palpable VMs can 
be made largely on the basis of clinical history and physical examination, 
diagnostic imaging is often required for the evaluation of deeper lesions or in the 
setting of an atypical history to allow differentiation from other malformations or 
nonmalformation lesions. Imaging may also be performed for confirmation or to 
alleviate persisting concerns regarding the possibility of malignancy. 
Conventional Radiography 
Because of limited soft tissue contrast resolution, there is little to be 
offered by conventional radiography for the evaluation and diagnostic work-up of 
VMs. Conventional radiography can reveal varying degrees of dystrophic 
calcification that can commonly occur within VMs and more rarely in LMs.4 The 
pathognomonic finding within VMs is the phlebolith caused by thrombosis and 
calcification.[4],[8], [19], [23], [29],  
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Ultrasonography 
Ultrasound is usually the first modality used in the imaging work-up of a 
suspected vascular malformation because it is widely available, low cost, 
noninvasive, and does not use ionizing radiation. On gray-scale imaging, VMs 
nearly always appear heterogeneous (98%). Relative to adjacent tissue, the 
lesions are usually hypoechoic (82%), but can be hyperechoic (10%) or isoechoic 
(8%).67 Tubular anechoic structures representing vascular channels are seen in a 
minority of cases (4%–50%).[37]and[67] The pathognomonic phlebolith, as expected, 
appears as a hyperechoic focus with acoustic shadowing; however, unfortunately 
this is only detected in 16% of cases.67 If near the skin surface, the lesions are 
compressible. On occasion the only sonographic finding is isoechoic skin 
thickening without discernible mass or vascular channels.66 
Color and pulsed Doppler analysis of the VMs reveal flow in 84% of 
lesions, with monophasic and biphasic flow seen in 78% and 6%, respectively. 
Only 16% reveal no discernible flow, which has been proposed may indicate 
lesion thrombosis or flow below detectible limits .67 
Computed Tomography 
CT is of limited use in the work-up of most focal VMs because of several 
factors. CT, even with contrast enhancement, usually provides poor lesion 
conspicuity relative to adjacent potentially critical structures and does not usually 
provide assessment of internal malformation vascular architecture, two variables 
that have significant impact on therapeutic decisions. On noncontrast CT, VMs 
are usually of low attenuation and appear homogeneous or, as is commonly the 
case, heterogeneous if infiltrated with adipose tissue.29 Contrast administration 
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results in a similar pattern of gradual peripheral to central enhancement as is 
seen in hepatic  
VMs; however, contrast CT can still underestimate lesion extent.[29]and[63] CT scan 
can identify dystrophic calcifications and phleboliths when present, and can be 
extremely helpful in providing detailed anatomic information regarding adjacent 
bony pathology if required.4 
MR Imaging 
The introduction of MR imaging has allowed a giant leap forward in the 
noninvasive assessment of vascular anomalies by providing superior lesion and 
soft tissue discrimination to CT, semiquantitative flow assessment, and three-
dimensional reconstruction, all without subjecting the patient to ionizing 
radiation.[4],[68]and[69]  As a result, MR imaging has become the imaging modality of 
choice for these lesions.[68]and[70] Not only can MR imaging influence therapeutic 
decision making by defining the internal architecture of a malformation and its 
relationship to adjacent critical structures, but it can also serve an objective 
method quantitatively to assess therapeutic outcomes through serial MR imaging 
monitoring of treated lesion size and signal characteristics.[4],[29],[68],[69]and[70] 
Recent advances now even use MR imaging for image guidance during 
percutaneous therapy of vascular malformations.[71], [72]and[73] The disadvantages 
of MR imaging are not unique to malformations, because imaging requires a 
cooperative, nonclaustrophobic patient and sometimes long scan duration for 
larger lesions. 
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The usual basic MR imaging protocol used in the evaluation of a 
suspected VM should ideally start with a spin-echo or fast spin-echo T1-weighted 
evaluation of the lesion morphology allowing maximal definition of tissue planes 
and relationship to critical osseous or neurovascular structures. This should be 
followed by fat-saturated T2-weighted and T2-weighted short tau inversion 
recovery sequences, which allow one to define maximal extent of the lesion. T1- 
and T2-weighted sequences should be performed in at least two planes. The 
identification of hemosiderin, dystrophic calcification, or phleboliths can be 
achieved through the use of gradient echo T2 -weighted sequences that can also 
aid in evaluation of high versus low flow. The study should be completed with 
pre–gadolinium- and post–gadolinium-enhanced fat-saturated T1-weighted 
imaging.[4],[29]and[70] 
VMs classically appear as either isointense or 
hypointense[4],[8],[29],[63],[70],[74]and[75] on T1-weighted sequences. They may appear 
more hyperintense,76 however, particularly if the lesion contains fat.75 The lesion 
can appear focal or diffuse, or demonstrate lobulated margins.70 A more 
heterogenous appearance can be identified in the setting of hemorrhage or 
thrombosis, and often dilated or serpiginous vascular structures can be identified 
compatible with abnormal veins.[29]and[63] Lower signal areas or signal voids may 
represent dystrophic calcification or phleboliths on all imaging 
sequences.[29],[69],[70]and[75] T2-weighed or short tau inversion recovery imaging of 
VMs consistently demonstrate high signal intensity[4], [8],[29],[63],[70],[74],[75],[76],[77]and[78] 
and reveal the fullest extent or infiltration at the margins of the lesion, often more 
so than that defined on T1-weighted imaging. In addition to calcifications or 
phleboliths, lower signal areas on T2 can be caused by either vascular channels 
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or fibrofatty septa.[29]and[75] Gradient echo imaging can demonstrate areas of low 
signal corresponding to calcification or hemosiderin.29 Gadolinium administration 
results in homogenous or heterogenous enhancement within the substance of a 
VM.[70]and[77] Gadolinium-enhanced fat-saturated sequences demonstrate the level 
of vascularity within the lesion and allow clear separation of the lesion from 
commonly inspissated or perilesional fat.[4]and[29] MR imaging can be used to 
monitor clinical outcomes after sclerotherapy with successful treatment resulting 
in reduction of lesion size.[9]and[37] Treated portions demonstrate increased 
heterogeneity, decreased T1 and T2 signal intensity, and decreased 
enhancement, and if necessary, allows for targeting of specific untreated regions 
for future therapy.[4]an[29] 
VMs are usually easily differentiated from other vascular malformations 
based on several criteria.   VMs are differentiated from high-flow malformations 
because the latter have low T1 and T2 signal and signal void among tangles of 
hypertrophied arteries, turbulent shunts, and engorged venous spaces that are 
focally higher signal on gradient echo.[63],[69], [70]and[76] Very importantly, AVMs 
characteristically lack a definable mass or soft tissue component quite unlike 
VMs.[70]and[79] Only rarely can an AVM demonstrate a pseudomass because of 
edema, fatty hypertrophy, diffuse atrophy, or confinement to a fascial 
compartment.[4] and [80] VMs are readily differentiated from macrocystic LMs 
because the latter reveal large cystic septated spaces that do not enhance with 
gadolinium.[63],[70],[76],[77]and[81] Occasionally, the septal walls may enhance causing 
“rings or arcs” or cyst walls may enhance when inflamed, such as with infection 
or after sclerotherapy.[70]and[77] Differentiating VMs from microcystic LMs can 
prove difficult. Because microcystic lesions consist of innumerable small spaces 
 27
beyond the resolution of MR imaging, a more homogenous VM-like appearance 
is seen that may minimally enhance or may not enhance at all.[70]and[77] Because 
conventional MR imaging is exquisitely sensitive but not specific for the detection 
and characterization of vascular malformations,82 all diagnoses have to be made 
in the context of clinical history and physical examination. As with any other 
noninvasive imaging, if MR imaging findings are atypical or suspicious or merely 
nonspecific, one should consider proceeding to diagnostic phlebography or 
angiography, or biopsy.[4] and [29] 
Direct Percutaneous Phlebography 
Direct percutaneous phlebography, as the name implies, involves direct 
fine-needle puncture of the lesion and contrast injection under fluoroscopy and is 
currently used in several distinct scenarios. The study provides the diagnostic 
gold standard for specificity in situations requiring confirmation of a VM that may 
be equivocal on previous imaging modalities, or for treatment planning, or to 
exclude the possibility of neoplasm in cases where biopsy is being contemplated. 
The technique can also be used in the evaluation of LMs. More commonly, direct 
percutaneous phlebography is performed as the initial diagnostic evaluation of 
venous (or lymphatic) malformation morphology and flow characteristics within 
the sclerotherapy procedure.[4]and[29]  
Diagnostic Angiography 
In current practice, there is no role for diagnostic angiography in the 
diagnostic work-up or management of purely low-flow vascular malformations if 
one follows a prescribed algorithm.[4]and[83]. Arteriography may have a role in the 
specialized work-up of mixed lesions that may have a high-flow component. 
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Historically, arteriography of VMs reveals either no findings, or a delayed mass-
associated venous or capillary blush with variable stasis, pooling, or 
puddling.[4]and[70] Feeding vessels are either normal or slightly enlarged and 
draining veins may be dilated.19 
Image-Guided Sclerotherapy of Venous Malformations Rationale 
 Within a VM, as in any vascular space, the endothelial cell serves as the 
“center of operations” controlling the local “milieu” of vascular channel growth and 
function and maintaining and restoring patency through processes of clearance 
and recanalization.84 The continued disordered growth controlled at the 
endothelial cell level is the factor most responsible for VM symptoms bringing 
patients to medical attention. It stands to reason that, short of resection, only 
therapy directed at the endothelial cell level is effective.[84]and[85] Because no 
corrective pharmacologic or genetic endothelial interventions have yet been 
conceived, only an endothelial-cidal approach can offer the potential to reduce, 
retard, or eradicate the disease process.  
 The technique of sclerotherapy induces this local endothelial damage by 
the selective intraluminal delivery of an endothelial-cidal agent or sclerosant into 
a chosen abnormal intravascular space that then exerts its injurious effect on the 
endothelial cell by direct contact in a dose-dependant manner.[8]and[84] Apart from 
the choice of agent, the therapeutic effect of sclerotherapy on a given endothelial 
surface is dependant on two major variables: the in vivo sclerosant concentration, 
and the length of time of sclerosant contact with the endothelial layer or “dwell-
time.”[4],[83]and[86] In vivo concentration is proportional to in vitro concentration, 
injection rate, and length of time of agent administration and is inversely 
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proportional to volume of distribution within the lesion. Lesion flow rate has an 
inverse proportional relationship with in vivo concentration and dwell time. The 
flow rate is fortunately low or negligible within VMs, as seen on Doppler67; this 
variable is of only nominal concern. All of these variables can be manipulated to 
varying degrees to optimize the therapeutic effect on the vascular endothelium of 
the lesion while minimizing nontarget trauma to nonmalformation structures within 
and adjacent to the lesion 
Major Sclerosing Agents 
 A number of sclerosing agents have been or are currently being used in 
the treatment of VMs that vary in degree of relative toxicity, viscosity, and 
complication profile. A number of sclerosing agents have been or are currently 
being used in the treatment of VMs that vary in degree of relative toxicity, 
viscosity, and complication profile 
Ethanol is probably the most widely used sclerosant because it is user-
friendly, relatively inexpensive, readily available, and has a long shelf-life.[87] and [88] 
As with all sclerosants, ethanol acts through direct contact with the vascular wall 
causing dehydration of endothelial cells, precipitation of the cytoplasm, followed 
by sloughing or denuding of this monolayer. The vascular wall fractures to the 
level of the internal elastic lamina and blood proteins precipitate.[84] and [89] Given 
the role of the endothelial cell in angiogenesis and directing removal of thrombus 
and debris, the elimination of the endothelial cell and its accompanying changes 
are thought to be responsible, at least by indirect evidence, for the relative 
permanence of occlusion and lack of recanalization seen after sclerotherapy with 
ethanol.[84] and [89]  
 30
Although ethanol is clearly a highly if not the single most effective agent in 
achieving vascular closure, it is also very toxic, with a low therapeutic index or 
ratio, and must be used with extreme caution.90 The agent must be given with 
superselective positioning beyond any reasonable doubt as to the possibility of 
normal tissue between delivery point and target. Nontarget embolization can 
occur whereby inflow into interstitial tissue leads to rapid penetration of vascular 
walls and devitalization of normal tissue.[86] and [89] As a result, one of the most 
common major ethanol-related complications is juxtalesional necrosis, particularly 
skin necrosis, thought to be the result of reflux into superficial venous channels or 
capillaries during the sclerotherapy procedure.91 In addition to skin necrosis, 
other commonly encountered complications encountered during the treatment of 
venous or vascular malformations with ethanol include nerve impairment or palsy 
and hemoglobinuria.[85], [86], [92], [93] and [94] Administration of intravascular ethanol 
has been noted to cause precapillary pulmonary arterial vasospasm with 
increased right heart pressures and right heart failure in rare cases.89 Sustained 
pulmonary hypertension has been noted in 30% of patients per ethanol treatment 
session, but does not seem to have a lasting effect, and does not seem to be 
correlated with total dose administered. There does not seem to be a tendency 
for increased pulmonary reactivity with multistage ethanol therapy87 Other rare 
complications reported are intoxication,93 bronchospasm,95 hyperthermia,96 
pulmonary embolus,85 cardiopulmonary collapse,97 and death.98 To reduce the 
incidence of local and systemic complications, it has been recommended that the 
administration of ethanol for any given sclerotherapy procedure not exceed 
1 mL/kg.84 In addition to this complication profile, the administration of ethanol is 
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invariably very painful and usually mandates general anesthesia during the 
procedure. 
Sodium tetradecyl sulphate                   
          Sodium tetradecyl sulphate (STS) is an anionic surfactant that appears as 
a white waxy solid; however, in injectable form, has a soapy consistency and 
contains 2% benzyl alcohol.84 STS is much less toxic than ethanol and acts by 
causing sludging of erythrocytes; thrombosis of the vessel; and obliteration of the 
vessel by intimal necrosis, adventitial fibrosis, and luminal collapse.148 This agent 
has historically been used extensively in the treatment of esophageal varices and 
varicose veins; however, after reports of nonvariceal use beginning in the 
1980s,[100], [150], [101], [102] and [103] STS has very gradually appeared in the literature 
for the treatment for VMs.[8], [83], [92], [90] and [99] STS clearly results in lower rates of 
skin necrosis, nerve impairment, and systemic complications.[83] and [99] In higher 
doses, however, urticaria, anaphylaxis, and hematuria have been reported.92 This 
agent has been found to be less effective at permanent closure of vascular 
structures within high-flow lesions.84 Similarly, within VMs, a lower rate of 
permanent closure is observed,[8] and [90] with larger versus smaller venous cavities 
demonstrating recurrence.83  
Polidocanol 
 Polidocanol is an increasingly popular nonionic surfactant that was initially 
developed as a topical anesthetic in 1936 but was later found to have a vascular 
sclerosing effect that made it unsuitable for parenteral use.[104] and [105] Being an 
anesthetic agent, its intravascular use is virtually painless; however, 1% lidocaine 
can be added to the agent to ensure minimal pain.106 Polidocanol consists of 95% 
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hydroxypolyethoxydodecane and 5% ethanol as a preservative, and is available 
in concentrations ranging from 0.25% to 4%.[104], [107] and [108] This detergent agent 
acts by causing rapid overhydration of endothelial cells, with consequent vascular 
injury and closure, and has direct effects on the intrinsic pathway of 
coagulation.109 It does not incite as much endothelial damage as ethanol, STS, or 
ethanolamine oleate.110 As such, there has been a relatively low rate of reported 
local complications, such as skin necrosis or nerve impairment; however, they 
can occur.[104] and [111] Systemic complications of hemolysis and hemoglobinuria 
and elevation of D dimers and thrombin-antithrombin III are relatively common112; 
however, more significant events, such as reversible cardiac arrest, have been 
reported.113  
Ethanolamine oleate 
Ethanolamine oleate is a salt of unsaturated fatty acids and, like other 
sclerosants, has been used previously in the treatment of gastroesophageal 
varices and works by two simultaneous mechanisms. The oleic portion of this 
agent induces a dose-related inflammatory response within the intima and 
penetrates the vascular wall, leading to a dose-related extra vascular 
inflammatory reaction and activating coagulation. The ethanolamine portion 
suppresses fibrin clot organization. In combination, the agent allows fibrosis and 
sclerosis to replace the lesion that may progress over time and appear in delayed 
manner.[114], [115] and [116] Ethanolamine oleate may have less of a penetrative effect 
beyond the vascular wall, particularly where a nerve runs along the lesion in 
question, and may have a wider safety margin than ethanol.117 Ethanolamine 
oleate has been used in both high-flow[117] and [118] and low-flow vascular 
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malformations[72], [86], [115] and [119] and is thought to have a low incidence of distal 
embolization.118 This sclerosant has been known to cause intravascular 
hemolysis, renal insufficiency, and hepatotoxicity in higher doses, however, and 
prophylactic haptoglobin administration may be necessary.[69], [86] and [117] To avoid 
this complication, some have recommended using no more than 1 mL of 5% 
ethanolamine solution120 and diluting the solution to 2.5% or 1.25% with the 
added benefit of less local irritation.115 
Alcoholic solution of zein 
 Alcoholic solution of zein is composed of zein solution, sodium 
amidotrizoate, oleum papaveris, and propylene glycol. The zein solution is made 
of a water-insoluble prolamine from corn gluten used to form the hard clear shells 
for coating foods and pharmaceutical products, creating a very viscous solution. 
Once administered, alcoholic solution of zein requires approximately 10 to 15 
minutes to solidify. The agent then remains relatively static in the lesion without 
passing into venous outflow and is allowed to exert a sustained sclerosant effect 
leading to necrosis, thrombosis, and fibrosis over the extended dwell time.[121] and 
[122]
 Alcoholic solution of zein is then degraded into amino and glutamic acids over 
approximately 11 days. Alcoholic solution of zein has been used to good effect 
within VMs.[121], [123], [124] and [125] The material also has been used in LMs and 
AVMs.[124], [126] and [127] The disadvantages of alcoholic solution of zein include its 
relative unavailability, usual need for general anesthesia, and possible delayed 
extrusion of the embolic material to the skin surface.[121] and [126] As such it is no 
longer considered a first-line agent. 
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Sodium morrhuate 
Sodium morrhuate is sodium salt of fatty acids in cod liver oil that was 
originally used to treat arthritic joints and varicose veins as a sclerosant, and has 
been used within VMs.90 It has been found, however, to be 1.5 to 4 times less 
effective than STS.101 
Historically, many other sclerosing or fixative agents have been used 
either within VMs or for other pathologic cystic phenomena including hypertonic 
50% dextrose, hypertonic saline, acetic acid, methylmethacrylate, triamcinolone, 
bleomycin, and tetracycline.[128]  
Direct Percutaneous Phlebography Technique 
Direct percutaneous phlebography and sclerotherapy should be performed 
in an angiography suite equipped with digital angiographic capabilities, real-time 
ultrasound, and an “in-room” ability to review and correlate with prior MR imaging 
or angiographic imaging. Except for the rare instance where diagnostic imaging is 
equivocal for VMs and direct diagnostic phlebography is performed as a purely 
diagnostic test, the patient usually requires at least conscious sedation and 
possibly local or regional block or general anesthesia. The patient is then 
positioned to allow best access to the lesion, and draped and prepared in a 
sterile fashion leaving all relevant access points to the lesion exposed. 
A standard instrument tray is assembled with the addition of clearly 
labeled syringes or containers of saline, iodinated contrast, and sclerosants. A 
20- to 27-gauge needle with short low-volume connector tubing or a butterfly 
needle is connected to a saline-filled syringe by a three-way stopcock. Whether 
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for purely diagnostic purposes or as a prelude to sclerotherapy, the direct 
percutaneous phlebogram classically begins with the percutaneous introduction 
of the needle into the substance of the VM under real-time ultrasound 
guidance[29] and [112] with or without fluoroscopic correlation.130  
For the period of sclerosant administration, removal of the saline syringe 
and addition of a second three-way stopcock with dual sclerosant syringes 
facilitates easy syringe exchanges that do not disturb the often precarious needle 
position within the canalicular channels of the VM).92 Once the VM has been 
adequately opacified with iodinated contrast and note is made of both volume of 
distribution and rate of flow, the chosen sclerosant is gently injected into the 
lesion at a corresponding rate and volume that gradually displaces the contrast 
from the region of the VM being treated.[4], [92] and [90] Intermittent aspiration should 
be performed to ensure a flashback of red blood is present, indicating 
maintenance of intravascular position and incomplete occlusion of the channel in 
question.92 As venospasm and vascular occlusion occur within the regions of the 
lesion that come into contact with the sclerosant, new pathways or territories may 
appear. Sclerosant delivery may be continued, or may require additional contrast 
to define better a new territory before continuing. Careful observation and 
monitoring is required during sclerosant delivery to assess for extravasation; 
overly rapid efflux of sclerosant into the venous outflow; resistance to injection; 
cessation of flashback of red blood; signs of major patient distress; or signs of 
skin blanching, which may indicate chemical toxicity or ischemia to the skin. Any 
one of these findings should prompt immediate cessation of further injection of 
sclerosant.[78], [90] and [129] If palpable, the operator should observe the degree of 
induration of the lesion over the course of sclerotherapy[99] and [130] and limit 
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administration as the lesion becomes firm. The vascular territory defined by 
phlebography on any given needle pass may only represent a portion of the 
lesion; repeated comparison should be made with the MR image or ultrasound in 
deciding if multiple needle placements for sclerotherapy are warranted.[83],[90] and 
[131]
 The procedure is terminated once an adequate volume of the VM is treated, if 
maximum allowable sclerosant dose is reached,90 or if the presence of 
intravascular or extravascular contrast obscures visibility of the lesion such that 
safe intraluminal sclerosant delivery cannot be ensured.   
The maximum allowable doses for ethanol are 1 mL/kg84; however, this 
dosage is rarely if ever reached. The maximum manufacturer's recommended 
dose of STS (for varicose veins) is 3 mL of 3% solution; however, some authors 
recommend a greater maximal allowable dose.90 Quoted maximal doses for 
polidocanol (for varicose veins) are 2 mg/kg/d,[113], [132] and [133] or 6 mL of 3% 
polidocanol solution.111 Some advocate a maximum of up to 300 mg or 10 mL of 
3% polidocanol solution, however, in the treatment of VMs.107 
Once administration of sclerosant has been completed and the lesion has 
been treated to the previously described end points, tourniquets or pneumatic 
cuffs, if used, can be left in place for 2 to 10 minutes to maximize dwell time and 
sclerosant effect.[90], [106] and [107] The sclerosant needles should be left in situ while 
the tourniquet or cuff is in position to avoid a significant increase in pressure 
within the lesion that could lead to extravasation and necrosis.90 If there is fear of 
an overly large volume of sclerosant exiting into the general circulation by 
draining veins on deflation of the tourniquet or cuff, the lesion can be aspirated 
through the sclerosant needle used to deliver the agent before deflation.107 If it is 
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suspected that a quantity of sclerosant has entered into the normal deep venous 
system, limb elevation and flushing of the system with an intravenous infusion 
more distally may lessen local injury. After final evaluation of the site by palpation 
and inspection for signs that may portend skin necrosis, such as blanching, 
ecchymoses, or retarded capillary refill, the needles can be removed. To allow 
vascular wall apposition and reduce intralesional volume and dilution effects, 
compression can be applied to the lesion immediately afterward. Direct 
compression can be applied merely for several minutes within the procedure 
room.[101] and [134] Many advocate some form of sustained compression with a 
dressing for 24 hours[83] and [106] to 3 to 7 days,[90] and [112] however, supplemented 
with elevation of the involved limb for 24 hours83 To commence anti-inflammatory 
therapy, ketorolac, 10 mg, can be administered parentally in the case room. If a 
significant quantity of ethanol was used as the sclerosant, some have advocated 
drawing a serum ethanol level.134 Immediately before the patient leaves the 
procedure room, a final examination of cutaneous and vascular integrity of the 
treated region should be performed and documented, including a perfunctory 
sensory motor function assessment if possible based on the patient's level of 
consciousness. 
 If sclerotherapy is contemplated in a superficial malformation, it is 
recommended that the needle be advanced through normal adjacent tissue en 
route to the lesion to avoid blood loss or extravasation along the tract during and 
after sclerotherapy.92 If the lesion is in close proximity to a nerve, a needle 
approach as far away as possible from the nerve is recommended and, if 
sclerotherapy is contemplated, intraprocedural nerve monitoring is 
recommended.74 As the needle is slowly advanced toward and into the 
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malformation, the syringe is gently and continuously aspirated on, until a 
flashback of blood is observed signifying intraluminal position of the needle.[4], [29] 
and [90]
 Once the flashback is observed, the needle tip is stabilized, and very 
minimal contrast is gently injected to confirm intraluminal and intralesional 
positioning. Then, low frame-rate digital subtraction phlebography or venography 
is performed during gentle contrast injection to confirm the presence or absence 
of VM and to establish that stable intraluminal access has been achieved.[28] and 
[90]
. 
The optimal spacing between sclerotherapy sessions, should the lesion 
require, ranges from 3 weeks to 3 months[29], [90] and [134] and may be preceded by 
an additional ultrasound examination[106] and [111] to evaluate the level of flow and 
regional involution to direct further therapy. Routine ultrasound evaluation of all 
patients at 1 month can be performed106 and provides the opportunity to reassess 
the patient and assess level of satisfaction and need for further therapy. Although 
some have advocated MR imaging follow-up as early as 1 to 3 months,107 
significant inflammatory changes within the lesion as a result of sclerotherapy 
need to resolve and involute before management decisions can be based on its 
findings. Except in very specific circumstances, MR imaging follow-up should 
occur 6 full months after the last sclerotherapy session29 MR imaging evaluation 
should demonstrate decreased lesion size, decreased T1 and T2 signal intensity, 
and decreased enhancement in successfully treated regions, and allows for 
specific targeting of unchanged regions on future sclerotherapy sessions if 
necessary.[4] and [29] After the MR imaging, a further in-person patient visit can then 
be scheduled, preferably in a multidisciplinary setting, where lesion tape-
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measurements, medical photography, review of imaging, and a discussion of the 
patient's status and expectations can guide further management if necessary. 
Complications of Sclerotherapy 
Complications resulting from sclerotherapy of VMs can be classified as 
minor and major, or local and systemic. Minor local complications include 
erythema, swelling, pain, and tenderness. Skin blistering can resolve completely 
or evolve into hyperpigmentation, skin ulceration, and necrosis; however, these 
complications are still considered to be minor in the literature.[135] and [90] Major 
local complications can include transient or permanent nerve impairment or 
paralysis, thrombophlebitis, deep venous thrombosis, muscular contracture,106 
and compartment syndrome. Major systemic complications of sclerotherapy for 
VMs, both observed and theoretic, include hemolysis, renal toxicity, pulmonary 
embolism, ocular disturbances, anaphylactic reactions, hypotension, 
bradyarrhythmia, and cardiopulmonary collapse29 Because most patients 
undergo multisession therapy; per patient complication rates are always 
significantly higher than per session rates. 
Choice of sclerosant is the most important variable in the quoted rates of 
complications. Ethanol is probably the most commonly used sclerosant in the 
treatment of VMs and, although probably the most efficacious, is clearly 
associated with the highest rates of complication.[4], [90] and [107] In by far the largest 
reported series using ethanol in 87 patients over 379 sessions,135 minor and 
major complications occurred in 12.4% of sessions and 27.9% of patients. A total 
of 8.8% of sessions resulted in erythema, blistering, or localized skin or 
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subcutaneous ulceration or necrosis that resolved with conservative 
management. A total of 1.5% resulted in deeper injury requiring surgical 
intervention. Transient and permanent nerve injury occurred as a consequence of 
0.8% and 0.5% of sessions, respectively.  
Deep venous thrombosis and pulmonary embolism occurred in 1.25% and 
0.25% of sessions, respectively. Minor limited chronic musculoskeletal symptoms 
occurred in 8% of patients, requiring conservative therapy, whereas 1.1% of 
patients experienced contracture requiring surgical correction. No evidence of 
transient pulmonary hypertension was identified in the 379 sessions. Other series 
using exclusively ethanol as the sclerosant for VMs quote complication rates that 
are consistent with those mentioned previously.[110], [136], [137], [131] and [134] 
Significantly lower complication rates are observed with STS sclerotherapy 
compared with ethanol. In the largest series to date using exclusively tetradecyl 
sulphate foam in 72 patients over 226 sessions,90 no major complications were 
observed. Minor complications occurred in 3.1% of sessions and 9.7% of 
patients. Complications included ulceration or skin necrosis in 2.2% of sessions 
or 6.9% of patients and either transient sensory deficit or urticaria, each occurring 
in 0.44% of sessions and 1.4% of patients. Other than venous thrombosis leading 
to monocular blindness from treatment of a juxtaocular lesion in a single 
patient,148 other studies using tetradecyl sulphate have observed comparably low 
purely minor complication rates ranging from 0% to 14%.[83], [99] and [101] 
Even lower complication rates have been observed with polidocanol 
sclerotherapy of VMs. Pain and marked swellings are the most commonly 
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encountered complications, occurring in 82% and 75% of patients, respectively. A 
total of 22% of treated patients can exhibit local erythema and induration.106 
Transient hyperpigmentation has been observed in 8% with epidermal necrosis 
or skin blistering occurring in 0% to 0.7%.[106], [107], [111] and [112] Skin necrosis (6%–
7% of patients) or inadvertent intra-arterial injection has been observed, resulting 
in necrosis or nerve impairment (4% of patients).[104] and [111] Transient limb 
numbness, hypotension, and bradyarrhythmias,107 and reversible cardiac 
arrest,113 have been described during the treatment of VMs with polidocanol. 
Sclerofoam has been observed traversing a patent foramen ovale (that is present 
in 20%–25% of adults) and may be responsible for rare transient ocular 
disturbances described in the varicosity literature. No definite right-to-left shunting 
complications have yet been described, however, during polidocanol foam 
treatment of VMs.104 
Ethanolamine oleate therapy results in mild erythema and inflammation in 
most patients for up to 72 hours with no significant reports of necrosis or nerve 
impairment.[72], [86] and [115] Similarly, in the largest series using alcoholic solution of 
zein for sclerotherapy of VMs,121 pain, swelling at the injection site, and low-grade 
fever were the most common complications. A total of 5% of patients experienced 
skin necrosis and focal extrusion of the alcoholic solution of zein contents, 
however, and 2.6% developed superficial thrombophlebitis. No significant 
complications have been reported in smaller series.[123] and [125] 
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Therapeutic Efficacy of Sclerotherapy 
Many clinical and imaging variables enter into the equation of determining 
degree of therapeutic benefit after sclerotherapy of a VM, making comparison 
between conservative, surgical, and various interventional radiologic treatment 
arms difficult. Most studies evaluating efficacy are retrospective and without 
objective pain scoring systems, which then introduce patient and investigator 
bias. Clinical outcomes are commonly divided into relatively arbitrary categories, 
such as excellent, good, fair, poor, or worse, based on reported patient 
symptoms that may also incorporate imaging based on change in lesion size. 
Relatively objective prelesion and postlesion size measurements obtained 
clinically and by imaging, however, are not necessarily well correlated with 
reduction in malformation-associated symptoms.90 It is also known that 
malformation size can be dynamic, and can change with dependent positioning 
and exercise at times of maximum symptoms and is difficult to assess by static 
resting state MR imaging. The total number of studies evaluating sclerotherapy of 
VMs is still relatively small and there are no prospective randomized trials 
between sclerosants or techniques. There are very few studies that correlate 
lesion morphology or location with outcome. Because of these issues, it is not 
surprising that no sclerosant or technique has yet proved itself to be clearly 
superior.9 
Despite these shortcomings, certain general trends predicting benefit can 
be derived based on lesion morphologic characteristics. As previously described 
by Dubois and coworkers,29 better results of sclerotherapy have been observed 
with cavitary lesions and dysmorphic VMs; however, dysmorphic lesions are 
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more prone to recurrence. Spongy pattern malformations are more difficult to 
treat, especially if intramuscular. With respect to the MR imaging grading system 
described by Goyal and coworkers, 78 a lower grade was clearly correlated with 
better response during ethanol sclerotherapy. Within grade 1 lesions, 71% had 
excellent response and none had a poor response. Grade 2A lesions 
demonstrated 22% excellent and 33% poor response. Grade 2B lesions had 27% 
excellent and 60% poor response. Grade 3 lesions revealed a not surprising 0% 
excellent response and 57% poor response. 
Quality of life assessments have been performed in patients undergoing 
ethanol sclerotherapy compared with matched controls, and have determined 
that most patients had decreased symptoms and did well posttherapy.137 Poorest 
outcomes were in those patients in whom the VM occupied an entire muscle or 
compartment. 
Predictions of recovery period and therapeutic effect after sclerotherapy 
for VMs have been reported based on the level of swelling postethanol treatment. 
In patients in whom there was marked swelling posttreatment, 80% had a 
prolonged recovery period and 100% had marked therapeutic effect. In those 
without marked swelling, 6% had prolonged recovery and 76% had therapeutic 
effect. 
In the largest of series using purely ethanol sclerotherapy for VMs,135 87 
patients receiving on average three sessions of therapy over 8.2 months, with an 
average follow-up of 18.2 months, and greater than 24 months in 72, technical 
success was observed in 95% of sessions with no evidence of recurrence. Fair to 
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good outcomes as defined earlier136 were observed in 95.4%, and poor in 4.6%. 
Other studies using ethanol report good to excellent results in 53% to 100%.[110], 
[137], [129], [131] and [134]
 In the largest series using purely STS sclerotherapy,90 72 
patients received an average of 3.1 sessions, with an average follow-up of 41 
months. A total of 15% of patients became asymptomatic, 28% had a good 
response, 24% were improved, 28% were unchanged, and 5.6% worsened. 
Pretherapy and posttherapy MR imaging performed in approximately half the 
patients revealed the VM had decreased in size in 54%, was unchanged in 31%, 
and had increased in size in 14%. Size reduction did not seem to correlate with 
symptomatic improvement. Other studies using STS alone or in conjunction with 
other therapies demonstrate patient benefit with moderate or excellent results in 
68% to 86%.[83] and [101] Clinically significant therapeutic benefit of polidocanol 
sclerotherapy, as defined in a number of studies, ranges from 78% to 100%.[154], 
[106], [107], [111] and [112]
 Ethanolamine oleate therapy within VMs has produced 
significant response in 87.5% to 100%.[72], [86] and [115] In the largest series using 
alcoholic solution of zein,171 excellent results were present in 74% of patients, 
with complete cure in 50% of cases. Other smaller alcoholic solution of zein 
series state complete therapy with sclerotherapy alone in 38% to 100% of 
patients.[123] and [125] 
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RESULTS AND ANALYSIS 
 
 
This was a one and half years prospective clinical study conducted to 
evaluate the role of direct percutaneous ethanol instillation in the treatment of 
venous malformations in the face and neck. Total 15 patients were included in 
the study. The results were analysed under the various headings are given 
below: 
 
Demographic Profile  
Distribution according to age 
Seven (46.6%) patients were in the age group of 16 - 25 Years and the mean age 
was 25.53  ± 13.752. (Table 4) 
Table – 4 
Distribution of patients according to the age group 
 
Age (years) n=15 % 
5 - 15 years 2 13.3 
16 - 25 Years 7 46.6 
26 - 35 Years 2 13.3 
36 - 45 Years 2 13.3 
>45 Years 2 13.3 
Mean ± SD 25.53 ± 13.752  
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Distribution according to sex 
 
The number of male patients was 10(66.7%) and female patients were 5 
(33.3%). The male: female ratio was 2:1. (Table 5 & Fig.5) 
 
Table – 5 
Distribution of patients according to sex 
 
  
Frequency Percent 
 F 5 33.3 
M 10 66.7 
Total 15 100.0 
 
 
 
Fig-5 
        
Distribution of patients according to sex 
 
33%
67%
female
male
 
 
 
 
 
 
 
 
 
 47
Distribution according to symptoms 
All the 15 (100%) patients presented with cosmetic deformity while 
10(66.7%) patients presented with pain and one (6.7%) with bleeding. (Fig.6) 
 
Fig – 6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Distribution of patients according to symptoms 
100 
66.7 
6.7 
Cosmetic deformity Pain Bleeding 
Series1 
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Distribution according to sites of venous malformation 
The lesion was present on the cheek in 12(80%) of patients while only one 
(6.7%) patient presented with nose lesion. (Fig.7) 
Fig - 7 
 
 
 
 
Distribution according to sites of venous malformation 
80 
13 13 
6.7 
13 
Cheek Lip Tongue Nose Temporal region 
Series1
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Distribution according to number of sclerotherapy sessions 
  Eleven (73.3%) patients needed only one session of sclerotherapy while 
2(13.3%) each, required 2 and 3 sessions respectively. (Table 6) 
Table – 6 
Distribution according to number of sclerotherapy sessions 
 
No. of 
sclerotherapy 
sessions 
n = 15 % 
 1 11 73.3 
2 2 13.3 
3 2 13.3 
Total 15 100.0 
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Distribution according to complications 
All the 15 (100%) patients developed post injection swelling and pain while 
one (6.7%) patient each developed blister and ulcer respectively. (Fig.8) 
 
Fig – 8 
 
 
 
 
 
Distribution according to follow up 
The maximum follow up was 14 months and minimum was 3 months with mean 
of 7.6.  
Distribution of patients according to complications 
 
100 100 
6.7 6.7 
Pain Swelling Blister Ulcer
Series1 
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Comparison of pre and post injection volume 
The maximum pre injection volume was 48ml and minimum was 4.5ml 
with median 21.the maximum post injection volume was 21 and minimum was 
1ml with median 6. (Table 7) 
Table – 7 
Comparison of pre and post injection volume  
Pre inj vol(ml) Post inj vol(ml) 
35 8 
48 8 
10 3 
12 4.5 
38 8 
36 9 
14 5 
10 3 
6 2 
22 7 
27 7 
21 6 
32 21 
21 6 
4.5 1 
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T-Test for pre and post injection volume 
Pre -Post Analysis 
Comparing the median values 21 and 6; p value was found to be .000 which is 
highly significant.  That is, there is a significant difference between the volumes (pre inj 
and post inj) 
(Table 8, 9 and Fig.9) 
 
 
Table - 8 
  Mean N Std. Deviation Std. Error Mean 
Pair 1 pre_inj_volume 22.43 15 13.189 3.405 
post_inj_vol 6.57 15 4.671 1.206 
 
 
 
Table – 9 
  Paired Differences 
t df 
Sig. (2-
tailed) 
  
Mean 
Std. 
Deviation 
Std. Error 
Mean 
95% Confidence 
Interval of the 
Difference 
  Lower Upper 
Pair 1 pre_inj_volume - 
post_inj_vol 15.867 10.827 2.796 9.871 21.863 5.676 14 .000 
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Fig – 9 
  
Box Plot – Pre and post of injection volumes  
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Correlation of Age with Volume Reduction 
  The scatter plot shows as age increases vol reduction is less for which 
Spearman’s rank correlation coefficient, r= -0.543 which is significant. 
Fig - 10 
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Grading of Lesions 
  In our study, 4(26%) patients showed good results while 9(60%) had fair results. 
(Table 10) 
Table – 10 
Grading of Lesions  
 
Good 
 
4(26%) 
Fair 9(60%) 
Poor 1(6.7%) 
 
 
 
 
 56
 
Discussion 
 
A vascular malformation is composed of dysmorphic vessels that are believed to 
be the result of faulty embryonic development. Depending on predominant channel they 
are subcategorized as arterial, capillary, lymphatic, and venous or combined92 .Out of all 
these subcategories venous malformations are found to be most common. 
 Venous malformations are common particularly in head and neck region. They 
present a wide spectrum, from isolated cutaneous or intramuscular varicosities to more 
complex anomalies involving several tissue planes. The most common site found in our 
series was cheek which is similar to study by Berenguer B et al138. With lesions in the 
face and neck, patient concern focuses on cosmetic considerations more than functional 
difficulties.139 Symptoms vary depending on the location of the lesions, which are soft, 
compressible, nonpulsatile masses that may cause sudden pain, and which may exhibit 
development of a firm mass that subsides within days.92 and 138 Even small venous 
malformations can cause severe pain. The most common presentations in our study 
were cosmetic deformity and pain which was similar to study by Berenguer B et al138 and 
Lee CH et al134. 
The diagnosis of venous malformations is based on careful history and clinical 
examination. MRI can be used to define the extent of the malformations of the face and 
neck, and define the pathway of venous drainage. 92, 139, 112 and 72 Venous malformations 
show high signal intensity on enhanced MR images, 112 and 72which can be used to define 
the muscles or organs involved. 
Venous malformations have been treated by a variety of techniques over the 
years, including irradiation, electrocoagulation, cryotherapy, intravascular magnesium or 
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copper needles, surgical excision, lasers, compression, and sclerotherapy. 72, 140 and 141All 
these techniques have their particular indications and limitations. Surgical excision is 
useful only for localised and limited lesions. Aggressive excision can lead to significant 
loss of motor function, cosmetic problems, nerve damage, or massive bleeding in 
patients with extensive involvement because of the complicated anatomy of the face and 
neck. 112 and 136 
Sclerotherapy has the advantage of no external scaring, and few complications in 
comparison with surgical treatment. There are various choices of agents for 
sclerotherapy: 5% sodium morrhuate, sodium tetradecyl sulphate, ethanolamine oleate, 
OK432, bleomycin, ethanol, and hypertonic saline, alone or in various combinations, 
have all been used.92, 138, 137,Ethanol is the most of often used due to its low cost, 
antiseptic quality, wide availability and easy of use; however, ethanol sclerotherapy 
requires general anaesthesia because the procedure is very painful.142 Direct 
percutaneous contrast injection into the cavity is also required to detect the lesion 
volume and the possibility of multiple compartments. 
The volume of ethanol to be injected is determined from the percutaneous 
contrast study. In our patients, one-third of the cavity volume of 99% ethyl alcohol was 
injected into the tumour cavities. 92,139 and 134 To achieve the required result and to minimise 
the flow of ethanol into normal venous drainage structures, we used rubber bands to 
compress the patients' foreheads and chins to occlude facial venous return. Repeated 
aggressive treatment is required for very large malformations because recanalisation can 
occur, and to reduce the risk of major morbidity from the ethanol injection. 92 and 136 In our 
study, 11(73.3%) patients required only one injection of sclerotherapy while 2(13.3%) 
each, required 2 and 3 sessions respectively. All patients experienced symptomatic or 
cosmetic improvement. We attempted to study the factors that might predict the 
results of sclerotherapy.  Only age and volume reduction were valuable 
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predictors.  There was lack of correlation of other variables such as sex, location 
and number of sclerotherapeutic sessions. Perhaps our failure to statistically 
confirm these impressions can be ascribed to the small size of our sample.  
Young patients showed a better response to treatment in our study .The interval 
between injections is usually 12 weeks, to allow time to determine whether 
abnormal venous channels persist and to allow local reactions to subside. 
Potential complications of sclerotherapy include local skin necrosis, 
transient nerve palsy, haemoglobinuria, blood loss, and anaphylaxis. 92, 139, 138, 72, 
141, 136, 142 and 135
  Two patients in this study experienced transient facial nerve 
palsy, which resolved spontaneously within 3–5 days. The major disadvantage of 
this treatment is severe complication can rarely occur and include acute 
pulmonary hypertension with cardio-pulmonary collapse.142 To avoid such a 
catastrophic situation, it is suggested to inject the ethanol slowly combined with 
rubber band compression. 137 and 142 Injection of ethanol produces marked tissue 
swelling because of a combination of intralesional thrombosis and edema. In our 
study, there were no major complications. However, all the patients had post 
injection swelling and pain which subsided over a period of few weeks. 
Thus, ethanol sclerotherapy is an effective alternative treatment for venous 
malformations of the head and neck, and it is wise to begin this treatment as 
early as possible once the diagnosis is made. Careful planning is essential to 
reduce the potential risks of the procedure, and long-term follow-up of patients is 
needed to detect any recurrence. 
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Algorithm showing the study plan 
 
 
 
 
  
 
 
 
 
 
               
                  3 months           
 
 
 
  
 
Assessment of volume and venous 
drainage with contrast 
No residual 
cavities 
Follow-up 
• Clinical 
• Imaging-MRI 
3 months 
Confirmation of diagnosis 
• Clinical 
• Imaging 
o MRI 
o USG 
Ethanol sclerotherapy 
Residual 
cavities  
Follow-up 
• Clinical  
• Imaging: USG 
 
GOOD FAIR POOR 
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Fate of Fair and Poor Response category group 
 
 
All the patients under these categories will be followed up over the next two 
years. Their lesions will be reassessed every 6 months both clinically and by 
imaging (ultrasound) for any residual lesion. Any residual cavitatory lesion will be 
given sclerosant injection while any solid localised lesion will be assessed for 
surgical excision. 
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   Summary 
This was a one and half years prospective clinical study conducted to 
evaluate the role of direct percutaneous ethanol instillation in the treatment of 
venous malformations in the face and neck. Total 15 patients were included in 
the study. 
• The Mean age of patients in our study is 25.53 years with age range of 5 – 52 
years. 
• The male: female ratio in our study was 2:1. 
• The most common symptom in our study was cosmetic deformity (100%). 
• The most common site was cheek seen in 12(80%) patients. 
• 73.3% of patients required only one injection of sclerotherapy. 
• There were no major complications in our study. 
• The mean follow up was 7.6 months. 
• Majority of patients showed significant reduction of volume of the lesion after 
sclerotherapy. 
• Young patients showed better response to treatment. 
• According to grading scale, 4(26%) patients showed excellent results while 
9(60%) had good results. 
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Conclusion 
Ethanol Sclerotherapy for Venous Malformations of face & Neck is a safe 
& effective treatment option and the risk of morbidity involved with surgical 
treatment can be substantially reduced by acceptance of ethanol sclerotherapy 
by direct percutaneous technique. 
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Patient Photographs 
Case - 5 
22y M 
Venous Malformation Left Neck
PRE THERAPY POST THERAPY
 
 
 
Pre  Axial Post  Axial
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(Contd)
Before Coronal After   Coronal
 
 
 
 
Case - 6 
 
 
27y M
Venous Malformation Right Cheek
PRE THERAPY POST THERAPY
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Before  Axial After  Axial
 
 
 
 
 
                                                         Case - 2 
 
5Y F
Venous Malformation Left Cheek & upper lip
Pre Post
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                                                           Case - 10 
5Y f
Venous Malformation right Cheek
preop Post op
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                                        Christian Medical College, Vellore 
Department of Plastic Surgery 
 A Prospective Non Randomized Clinical Study to Evaluate the Role of Direct 
Percutaneous Ethanol Instillation in the Treatment of Venous Malformations in the 
Face and Neck 
Information sheet 
You are being requested to participate in a study to see the effect of ethanol instillation in 
the treatment Venous Malformations in the Face and Neck. There are other sclerosing 
agents that can help with these but ethanol is the most reliable among them with least 
chances of recurrence. We hope to include about 15 people from this hospital in this 
study. 
 
How will the treatment with ethanol instillation help you? 
Direct Percutaneous Instillation of ethanol will help in obliteration of the malformation to 
complete or near complete levels thus helping in providing you with relief from your 
symptoms with the advantage of no external scarring and few complications as 
compared to surgical treatment. 
 
Does treatment with ethanol have any side effects? 
Potential risks to participants include local skin discoloration with blistering, transient nerve 
palsy, blood in urine, blood loss, and anaphylaxis. Rarely it may affect the heart with a potential 
for cerebral intoxication which can be prevented.  
 
If you take part what will you have to do? 
Percutaneous Ethanol (99.5% ethyl alcohol) Sclerotherapy will be used under fluoroscopy  
guidance using intravenous general anesthesia. You will be examined with Magnetic 
Resonance Imaging to evaluate the possible remaining extent of venous malformation 
after 12 weeks. Repeated course of injection 99.5% ethanol may be administered after an 
interval of 12 weeks from the previous injection if abnormal venous channels persist. 
Treatment success will be determined by reduction in lesion size.   
You will be expected to come for a review to the hospital 12 weeks after first cycle and 
again after 12 weeks if need be.  
Can you withdraw from this study after it starts? 
 80
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. In addition, if you experience any serious 
side effects , the study will be stopped and you may be given additional treatment.  
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you but if you do develop any side effects or 
problems due to the study, these will be treated at no cost to you. We are unable to 
provide any monetary compensation, however.  
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your medical 
notes and photographs may be reviewed by people associated with the study, without 
your additional permission, should you decide to participate in this study.  
 
If you have any further questions, please ask       Dr.Shashank Lamba, Department of Plastic 
Surgery, CMC, and Vellore. Ph.04164212017. email id : shashanklamba@gmail.com 
 
 
 
 
 
 
 
 
                       
 
 
 
 
 
 
 81
  CONSENT TO TAKE PART IN A CLINICAL TRIAL 
 
Study Title: A Prospective Non Randomized Clinical Study to Evaluate the Role of 
Direct Percutaneous Ethanol Instillation in the Treatment of Venous Malformations 
in the Face and Neck 
 
Study Number: 
 
Participant’s name:  
 
Date of Birth / Age (in years): 
 
 
 
 
I_____________________________________________________________ 
___________, son/daughter of  ___________________________________ 
 
(Please tick boxes) 
Declare that I have read the information sheet provide to me regarding this study and 
have clarified any doubts that I had. [ ] 
I also understand that my participation in this study is entirely voluntary and that I am 
free to withdraw permission to continue to participate at any time without affecting my 
usual treatment or my legal rights [ ] 
 
I understand that I will receive free treatment for any study related injury or adverse 
event but I will not receive and other financial compensation [ ] 
I understand that the study staff and institutional ethics committee members will not need 
my permission to look at my health records even if I withdraw from the trial. I agree to 
this access [ ]  
I understand that my identity will not be revealed in any information released to third 
parties or published [ ]   
I voluntarily agree to take part in this study [ ] 
 
Name: 
Signature of the Patient/Parent/Guardian: 
 82
Date: 
 
Name of witness: 
Relation to participant: 
Date: 
 1
     Symptoms site 
sno age sex diagnosis no of sessions  
of 
sclerotherapy 
cosmetic  
deformity 
pain bleeding cheek  Lip 
1 6 f Venous Malformation Left Cheek 3 y y n y n 
2 5 f Venous Malformation left Cheek upper lip& temporal region 3 Y y y y y 
3 36 m Venous malformation left cheek 2 Y n n y n 
4 22 m Venous malformation Right Cheek lip & tongue 1 Y y n y y 
5 22 m Venous malformation left neck 1 Y n n n n 
6 27 m Venous malformation Right cheek 1 Y y n y n 
7 18 m Venous malformation right Cheek 2 Y n n y n 
8 51 f Venous malformation Right Cheek  1 Y y n y n 
9 52 F Venous malformation (R)   temporal region 1 Y y n n n 
10 20 F Venous malformation (R)  cheek 1 Y n n y n 
11 16 M Venous Malformation Right Cheek & tongue 1 Y y n y n 
12 26 M Venous Malformation Right Cheek  1 Y n n y n 
13 22 m Venous Malformation Left Cheek  1 Y y n y n 
14 38 m Venous Malformation Left Cheek  1 Y y n y n 
15 22 m Venous malformation root of nose 1 y y n n n 
 
 2
 
 site  Complication  
Pain 
    
site  
tongue 
root 
 of 
nose 
temporal 
 region 
Pain   
swelling 
 
 blister 
  
ulcer 
pre inj 
volume 
post inj 
vol 
follow 
up 
 
(months) 
 
n n n y y n n 35 8 9  
n n y y y y y 48 8 9  
n n n y y n n 10 3 12  
y n n y y n n 12 4.5 10  
n n n y y n n 38 8 14  
n n n y y n n 36 9 10  
n n n y y n n 14 5 9  
n n n y y n n 10 3 9  
n n y y y n n 6 2 8  
n n n y y n n 22 7 4  
y n n y y n n 27 7 4  
n n n y y n n 21 6 3  
n n n y y n n 32 21 3  
n n n y y n n 21 6 3  
n y n y y n n 4.5 1 8  
 
